

1 Estimating the generation time for 2 SARS-CoV-2 transmission using 3 household data in the United States, 4 December 2021 – May 2023

5 Louis Yat Hin Chan¹, Sinead E. Morris^{1,9}, Melissa S. Stockwell², Natalie M. Bowman³, Edwin Asturias⁴,
6 Suchitra Rao⁴, Karen Lutrick⁵, Katherine D. Ellingson⁵, Huong Q. Nguyen⁶, Yvonne Maldonado⁷, Son H.
7 McLaren², Ellen Sano², Jessica E. Biddle¹, Sarah E. Smith-Jeffcoat¹, Matthew Biggerstaff¹, Melissa A.
8 Rolfes¹, H. Keipp Talbot⁸, Carlos G. Grijalva⁸, Rebecca K. Borchering¹, Alexandra M. Mellis¹, RVTN-
9 Sentinel Study Group

- 10 1. Centers for Disease Control and Prevention
- 11 2. Columbia University Irving Medical Center
- 12 3. University of North Carolina at Chapel Hill
- 13 4. University of Colorado School of Medicine and Children’s Hospital Colorado
- 14 5. University of Arizona
- 15 6. Marshfield Clinic Research Institute
- 16 7. Stanford University
- 17 8. Vanderbilt University Medical Center
- 18 9. Goldbelt Professional Services

19 * Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30329,
20 US (LouisChan@cdc.gov)

21 Word count

- 22 • 253 (abstract)
- 23 • 1983 (main text)

24 Abstract

25 Background

26 Generation time, representing the interval between infection events in primary and secondary cases, is
27 important for understanding disease transmission dynamics including predicting the effective
28 reproduction number (R_t), which informs public health decisions. While previous estimates of SARS-CoV-
29 2 generation times have been reported for early Omicron variants, there is a lack of data for subsequent
30 sub-variants, such as XBB.

31 Methods

32 We estimated SARS-CoV-2 generation times using data from the Respiratory Virus Transmission
33 Network – Sentinel (RVTN-S) household transmission study conducted across seven U.S. sites from
34 December 2021 to May 2023. The study spanned three Omicron sub-periods dominated by the sub-
35 variants BA.1/2, BA.4/5, and XBB. We employed a Susceptible-Exposed-Infectious-Recovered (SEIR)

36 model with a Bayesian data augmentation method that imputes unobserved infection times of cases to
37 estimate the generation time.

38 Findings

39 The estimated mean generation time for the overall Omicron period was 3.5 days (95% credible interval,
40 CrI: 3.3-3.7). During the sub-periods, the estimated mean generation times were 3.8 days (95% CrI: 3.4-
41 4.2) for BA.1/2, 3.5 days (95% CrI: 3.3-3.8) for BA.4/5, and 3.5 days (95% CrI: 3.1-3.9) for XBB.

42 Interpretation

43 Our study provides estimates of generation times for the Omicron variant, including the sub-variants
44 BA.1/2, BA.4/5, and XBB. These up-to-date estimates specifically address the gap in knowledge
45 regarding these sub-variants and are consistent with earlier studies. They enhance our understanding of
46 SARS-CoV-2 transmission dynamics by aiding in the prediction of R_t , offering insights for improving
47 COVID-19 modeling and public health strategies.

48 Funding

49 Centers for Disease Control and Prevention, and National Center for Advancing Translational Sciences.

50 Introduction

51 The generation time is a fundamental epidemiological concept for understanding infectious disease
52 transmission dynamics and represents the time between beginning of infection events in primary and
53 secondary cases. Accurate generation time estimation is important for predicting the effective
54 reproduction number (R_t) [1, 2], which helps inform situational awareness and public health decisions.

55 Previous estimates of SARS-CoV-2 generation times [3, 4, 5, 6] have been reported using data through
56 the early SARS-CoV-2 Omicron variant period (e.g., sub-variant BA.1). However, there is a lack of
57 estimates for more recent SARS-CoV-2 Omicron variant periods of dominance (e.g., sub-variant XBB),
58 despite evidence showing that generation times have substantially decreased over the course of the
59 pandemic, particularly across the Alpha, Delta, and Omicron variants [7]. This trend has corresponded to
60 substantial increases in population immunity, and the emergence of distinct Omicron sub-variants,
61 which may have impacted the generation time of SARS-CoV-2 [8].

62 In this study, we adapted a previously published method [9] to estimate SARS-CoV-2 generation times
63 using data from more recent SARS-CoV-2 Omicron variant periods specifically the sub-variants BA.1/2,
64 BA.4/5, and XBB.

65 Methods

66 Household data

67 Participants were enrolled in a case-ascertained household transmission study, called the Respiratory
68 Virus Transmission Network – Sentinel (RVTN-S), from seven sites across the U.S., 2021–2023 [10, 11,
69 12, 13]. Individuals diagnosed with COVID-19 were enrolled, along with their household contacts, within
70 7 days of the initial illness onset within the household. Participants were then monitored prospectively
71 for 10 days, and during this follow-up period participants reported daily symptoms, including fever
72 (including feeling feverish and chills), cough, sore throat, runny nose, nasal congestion, fatigue (including
73 feeling run-down), wheezing, trouble breathing (including shortness of breath), chest tightness

74 (including chest pain), loss of smell or loss of taste, headache, abdominal pain, diarrhea, vomiting, and
75 muscle or body aches. Daily nasal swabs were also collected and tested for SARS-CoV-2 via RT-PCR.

76 **Estimating the generation time**

77 We employed a mechanistic Susceptible-Exposed-Infectious-Recovered (SEIR) compartmental model
78 and used a Bayesian Markov chain Monte Carlo (MCMC) approach for parameter estimation and data
79 augmentation, as proposed by Hart et al. [9]. The data augmentation MCMC approach, based on the
80 methodology from a household transmission modeling study by Cauchemez et al. [14], was also applied
81 in previous studies [15, 16]. We imputed symptom onsets and infection times of cases to estimate both
82 intrinsic and realized household generation times. The intrinsic generation time assumes no depletion of
83 susceptible individuals, reflecting infection in the community with an unlimited supply of susceptible
84 individuals. In contrast, the realized household generation time accounts for a gradual reduction in the
85 number of susceptible individuals as people are infected within the household setting.

86 The SEIR model incorporates three infectious compartments: asymptomatic, pre-symptomatic, and
87 symptomatic stages. After infection, individuals enter a non-infectious exposed phase before
88 progressing to an infectious state through one of two pathways: either remaining asymptomatic or
89 developing symptoms following a pre-symptomatic phase. Consequently, transmission can occur before
90 the onset of symptoms, depending on the length of the incubation period. We assumed the incubation
91 period had a mean of 2.6 days and a standard deviation (SD) of 1.0 days for the Omicron variant [17].
92 We also conducted a sensitivity analysis by assuming a longer incubation period with a mean of 4.1 days
93 and an SD of 2.7 days [3].

94 We also estimated the overall infectiousness, which describes the expected number of household
95 transmissions generated by a single symptomatic infected primary case.

96 We compared estimates for each sub-period to the overall Omicron variant period by calculating the
97 overlapping index, which measures posterior distribution similarity [18, 19]. Values near 100% indicate
98 high similarity with minimal differences, while values close to 0% suggest low similarity with significant
99 differences.

100 The estimation was performed in R (version 4.3.1) with 1,000,000 MCMC iterations, discarding the initial
101 20% as burn-in and obtaining posterior distributions by thinning every 100 iterations. Each MCMC chain
102 took approximately 48 hours to run on a single core of a high-performance computing cluster. The code
103 for the estimations is available at <https://github.com/CDCgov/covid-generation-time-us>.

104 **Ethics statement**

105 This study was reviewed and approved by the IRB at Vanderbilt University Medical Center (see 45 C.F.R.
106 part 46.114; 21 C.F.R. part 56.114).

107 **Role of the funding source**

108 L. Y. H. C., J. E. B., S. E. S. J., M. B., M. A. R., R. K. B., A. M. M. are employees of the CDC. The CDC was
109 involved in the design of the household study, and accessing, and verifying the data. The National Center
110 for Advancing Translational Sciences (NCATS) had no role in the study design, data collection, data
111 analysis, data interpretation, writing of the report, or the decision to submit the paper for publication.

112 Results

113 Household data

114 We enrolled 745 households with a single primary case (i.e., only one individual within a household
115 exhibited symptoms on the earliest onset date) with laboratory-confirmed SARS-CoV-2, along with their
116 1,334 household contacts, totaling 2,079 individuals including both primary cases and household
117 contacts. The study period spanned from December 2021 to May 2023, encompassing the period when
118 the Omicron variant predominated in the U.S. This period was further categorized into three sub-periods
119 dominated by the sub-variants BA.1/2 (December 18, 2021 – June 17, 2022), BA.4/5 (June 18, 2022 –
120 January 14, 2023), and XBB (January 15, 2023 – May 1, 2023) [20, 21].


121 Of 2079 participants, all of whom had at least two valid SARS-CoV-2 PCR tests [22], 69.4% tested positive
122 and reported symptoms (symptomatic infected), 8.5% tested positive but never reported symptoms
123 (asymptomatic infected), and 22.1% tested negative (uninfected) regardless of symptoms (Table 1). Over
124 the study period, the proportion who remained uninfected increased from 18.5% during the BA.1/2 sub-
125 period to 29.0% during the XBB sub-period.

Period	Number of participants (households)	Symptomatic infected % (n/N)	Asymptomatic infected % (n/N)	Uninfected % (n/N)
All Omicron	2079 (745)	69.4% (1443/2079)	8.5% (177/2079)	22.1% (459/2079)
BA.1/2	569 (200)	72.9% (415/569)	8.6% (49/569)	18.5% (105/569)
BA.4/5	1090 (389)	69.4% (756/1090)	9.4% (102/1090)	21.3% (232/1090)
XBB	420 (156)	64.8% (272/420)	6.2% (26/420)	29.0% (122/420)

126 *Table 1. Participant symptom and infection status by SARS-CoV-2 variant periods: All Omicron (December 2021 – May 2023),*
127 *and sub-variants BA.1/2 (December 18, 2021 – June 17, 2022), BA.4/5 (June 18, 2022 – January 14, 2023), and XBB (January 15,*
128 *2023 – May 1, 2023).*

129 The generation time for the overall Omicron variant period

130 For the overall Omicron variant period, we found a mean intrinsic generation time of 3.5 days (95%
131 credible interval, CrI: 3.3-3.7) and a mean realized household generation time of 3.0 days (95% CrI: 2.8-
132 3.1) (Figure 1 and Supplemental Table S1). In the sensitivity analysis, assuming the longer incubation
133 period, we found a mean intrinsic generation time of 3.6 days (95% CrI: 3.4–3.9) and a mean realized
134 household generation time of 2.6 days (95% CrI: 2.3–2.9), indicating that the estimates are insensitive to
135 changes in the assumed incubation period.



136

137 *Figure 1. Posterior distribution of mean intrinsic generation time categorized by SARS-CoV-2 variant periods: Omicron*
138 *(December 2021 – May 2023), and sub-variants BA.1/2 (December 18, 2021 – June 17, 2022), BA.4/5 (June 18, 2022 – January*
139 *14, 2023), and XBB (January 15, 2023 – May 1, 2023). The blue violin areas represent the kernel densities. The superimposed box*
140 *plots show the median values and interquartile ranges. The white dots show the mean values.*

141 The generation time for the sub-variant periods

142 The estimates during the sub-periods were similar with more than 40% overlapping to those of the
143 overall Omicron period (Table S1). The mean intrinsic generation time for the BA.1/2 sub-period was
144 slightly longer at 3.8 days (95% CrI: 3.4-4.2). The mean intrinsic generation time for the BA.4/5 and XBB
145 sub-periods was 3.5 days (BA.4/5: 95% CrI: 3.3-3.8; XBB: 95% CrI: 3.1-3.9). The mean realized household
146 generation time for each variant sub-period ranged between 2.9 and 3.1 days (BA.1/2: 3.1 days, 95% CrI:
147 2.9-3.4; BA.4/5: 2.9 days, 95% CrI: 2.7-3.2; XBB: 3.1 days, 95% CrI: 2.8-3.4).

148 The overall infectiousness

149 The overall infectiousness during the overall Omicron period was 2.5 (95% CrI: 2.4-2.7). This means that,
150 on average, each symptomatic primary case was responsible for approximately 2.5 secondary infections
151 within the household. Additionally, we observed a substantial decrease across each sub-period, starting
152 at 2.8 (95% CrI: 2.5-3.2) during the BA.1/2 sub-period, followed by a slight decline to 2.7 (95% CrI: 2.4-
153 2.9) with 61% overlapping during the BA.4/5 sub-period, and then a significant drop to 2.0 (95% CrI: 1.6-
154 2.3) with only 3% overlapping during the XBB sub-period (Supplemental Figure S1).

155 Discussion

156 Our estimated mean intrinsic generation time for the overall Omicron variant period was 3.5 (95% CrI:
157 3.3-3.7) days, which is shorter than the estimates for earlier periods of the Delta (4.7 days, 95% CrI: 4.1-
158 5.6), Alpha (5.5 days, 95% CrI: 4.7-6.5) and wild-type variants (5.9 days, 95% CrI: 5.2-7.0) [16, 9]. Our
159 results align with a previous systematic review and meta-analysis [7] that demonstrated a decrease in

160 the generation time (and incubation period) across the Alpha, Delta, and Omicron variants from 2021 to
161 2023.

162 This decreasing trend in the generation time may be influenced by a combination of factors. These
163 factors can both shorten the generation time and lower the overall infectiousness, as observed across
164 different Omicron sub-variant periods, partly because fewer transmissions occur in the later stages of
165 the infectious period. These include (1) less infectious infectors due to biological changes in the
166 pathogen, such as specific virological characteristics of the variants/sub-variants, altered viral shedding
167 patterns, or reduced viral load that lowers virus transmissibility; (2) less susceptible contacts due to
168 higher population immunity resulting in fewer successful transmissions; and (3) behavioral changes,
169 such as reduced direct contact with household members and more routine contact with others due to
170 the relaxation of pandemic mitigation measures [8]. However, the exact underlying reasons for this
171 trend remain uncertain.

172 The shorter generation time suggests transmission occurred earlier, implying faster transmission
173 dynamics, which has implications for public health measures. If it was primarily driven by virologic
174 factors or altered viral shedding patterns, isolation periods might be shortened and focused more
175 intensively on the early days. Importantly, we observed a decrease in the overall infectiousness between
176 the Omicron sub-variant periods. Despite the principle that a shorter generation time does not
177 necessarily correlate with higher overall infectiousness, the combination of a shorter generation time
178 paired with reduced infectiousness suggests that transmission might have occurred faster during the
179 XBB sub-period compared to the earlier Omicron sub-periods, although the overall number of
180 transmission events was lower.

181 Our intrinsic generation time estimates exceed a previous estimate of 2.9 days [3], which is currently
182 used to predict R_t and to infer the current epidemic growth status for states and territories in the U.S.
183 [1]. This suggests that some current efforts to forecast or model COVID-19 may rely on earlier estimates,
184 which could introduce biases. For example, given historical surveillance data, an underestimated
185 generation time would overestimate R_t and prediction trends. Updating generation time estimates to
186 reflect more recent data and current community transmission settings could improve the accuracy of
187 real-time infection trend predictions [2].

188 Our estimated realized household generation time for the overall Omicron variant period was 3.0 days
189 (95% CrI: 2.8-3.1), half a day shorter than the intrinsic generation time. Similar estimates were found in
190 earlier studies [3, 4, 5], and a pooled mean for Omicron BA.1 of 3.0 days (95% confidence interval, CI:
191 2.5-3.5) [7] closely matches our estimates for the BA.1/2 sub-period at 3.1 days (95% CrI: 2.9-3.4).
192 Furthermore, Wang et al. [6] found that the mean realized household generation time of Omicron BA.5
193 variants was 2.8 days (95% CrI: 2.4-3.5), also closely matching our estimate for the BA.4/5 sub-period at
194 2.9 days (95% CrI: 2.7-3.2). This consistency confirms the robustness of our estimates.

195 A limitation of our study is that we estimated the generation time across the entire study population,
196 regardless of prior immunity from vaccination or previous infection. Our objective was to provide more
197 up-to-date estimates that reflect the combined effects of shifting population immunity, behavioral
198 changes, and evolving viral lineages, rather than to estimate specific generation times by immune
199 status. While previous research [16] has shown that fully vaccinated individuals may experience slightly
200 longer generation times, our estimates are intended to capture the broader trends across the
201 population. It is worth noting that study participants may not be representative of the general

202 population, such as correlations due to cluster sampling not being addressed. Another limitation is that
203 we did not consider external infection routes outside the households. Household members might have
204 been infected by the community, leading to an overestimation of the overall infectiousness.

205 Conclusions


206 Based on SARS-CoV-2 household transmission data collected from December 2021 to May 2023 in the
207 U.S., we present updated estimates of the intrinsic and realized household generation time. These
208 estimates offer valuable insights into the transmission dynamics of SARS-CoV-2 within communities and
209 households. Our results are crucial for enhancing COVID-19 modeling and public health strategies and
210 highlight the necessity of ongoing evaluation of transmission patterns for optimal outbreak
211 management.

212

213 **Supplementary material**

	All Omicron	BA.1/2	BA.4/5	XBB
Mean intrinsic generation time (days)	3.5 (3.3-3.7)	3.8 (3.4-4.2)	3.5 (3.3-3.8)	3.5 (3.1-3.9)
SD of intrinsic generation time (days)	2.1 (1.9-2.3)	2.2 (1.8-2.7)	2.1 (1.8-2.4)	1.8 (1.4-2.2)
Mean realized household generation time (days)	3.0 (2.8-3.1)	3.1 (2.9-3.4)	2.9 (2.7-3.2)	3.1 (2.8-3.4)
SD of realized household generation time (days)	1.8 (1.6-1.9)	1.8 (1.5-2.0)	1.8 (1.6-2.0)	1.5 (1.3-1.8)
Mean serial interval (days)	3.4 (3.2-3.6)	3.6 (3.3-4.1)	3.4 (3.1-3.7)	3.3 (2.9-3.7)
SD of serial interval (days)	2.2 (2.0-2.4)	2.3 (2.0-2.8)	2.3 (2.0-2.6)	1.9 (1.5-2.4)

214 *Table S1. Posterior mean (95% CrIs) of estimates categorized by SARS-CoV-2 variant periods: Omicron (December 2021 – May*
 215 *2023), and sub-variants BA.1/2 (December 18, 2021 – June 17, 2022), BA.4/5 (June 18, 2022 – January 14, 2023), and XBB*
 216 *(January 15, 2023 – May 1, 2023).*



217 *Figure S1. Posterior distribution of overall infectiousness (expected number of household transmissions generated by a single*
 218 *symptomatic infected primary case) categorized by SARS-CoV-2 variant periods: Omicron (December 2021 – May 2023), and*
 219 *sub-variants BA.1/2 (December 18, 2021 – June 17, 2022), BA.4/5 (June 18, 2022 – January 14, 2023), and XBB (January 15,*
 220 *2023 – May 1, 2023). The blue violin areas represent the kernel densities. The superimposed box plots show the median values*
 221 *and interquartile ranges. The white dots show the mean values.*

223

224 Author contributions

	1	2	3	4	5	6	7	8	9	10	11	12	13	14
LYHC	Y	-	Y	-	Y	Y	-	-	Y	-	Y	Y	Y	Y
SEM	-	-	-	-	Y	Y	-	-	-	-	-	-	-	Y
MSS	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
NMB	-	Y	-	-	Y	-	-	-	-	-	-	-	-	Y
EA	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SR	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
KL	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
KDE	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
HQN	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
YM	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SHM	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
ES	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
JEB	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
SESJ	-	Y	-	-	-	-	-	-	-	-	-	-	Y	Y
MB	-	-	-	-	-	-	-	-	-	Y	-	-	-	Y
MAR	-	Y	-	-	-	-	-	-	-	-	-	-	-	Y
HKT	-	Y	-	Y	-	-	-	-	-	-	-	-	-	Y
CGG	-	Y	-	Y	-	-	-	-	-	-	-	-	-	Y
RKB	Y	-	Y	-	Y	Y	-	-	-	Y	-	-	-	Y
AMM	Y	Y	Y	-	Y	Y	Y	Y	-	Y	-	-	Y	Y

225 ... choose from the following items: <https://credit.niso.org>

- 226 1. Conceptualization
- 227 2. Data curation
- 228 3. Formal analysis
- 229 4. Funding acquisition
- 230 5. Investigation
- 231 6. Methodology
- 232 7. Project administration
- 233 8. Resources
- 234 9. Software
- 235 10. Supervision
- 236 11. Validation
- 237 12. Visualization
- 238 13. Roles/Writing - original draft
- 239 14. Writing - review & editing.

240 Acknowledgements

- 241 • The authors thank the following members of the Respiratory Virus Transmission Network –
- 242 Sentinel (RVTN-S) study teams:
- 243 a. Vanderbilt University Medical Center: Chris Lindsell, Judy King, John Meghreblian,
- 244 Samuel Massion, Brittany Creasman, Lauren Milner, Andrea Stafford Hintz, Jorge
- 245 Celedonio, Ryan Dalforno, Maria Catalina Padilla-Azain, Daniel Chandler, Paige Yates,

- 246 Brianna Schibley-Laird, Alexis Perry, Ruby Swaimn, Mason Speirs, Erica Anderson,
247 Suryakala Sarilla, Amelia Dodds, Dayton Marchlewski, Timothy Williams, Afan Swan,
248 Onika Abrams, Jackson Resser, Ine Sohn, Cara Lwin, Hsi-nien (Jubilee) Tan, Stephen
249 Yeargin, James Grindstaff, Heather Prigmore, Jessica Lai, Zhouwen Liu, James D.
250 Chappell, Marcia Blair, Rendie E. McHenry, Bryan P. M. Peterson, Lauren J. Ezzell.
251 b. Columbia University: Lisa Saiman, Raul A. Silverio Francisco, Anny L. Diaz Perez, Ana M.
252 Valdez de Romero.
253 c. Stanford University: Rosita Thiessen, Marcela Lopez, Alondra A. Aguilar, Emma Stainton,
254 Grace K-Y. Tam, Jonathan Altamirano, Leanne X. Chun, Rasika Behl, Samantha A.
255 Ferguson, Yuan J. Carrington, Frank S. Zhou.
256 d. Marshfield Clinic Research Institute: Edward A. Belongia, Hannah Berger, Vicki Moon,
257 Gina Burbey, Leila Deering, Brianna Freund, Garrett Heuer, Sarah Kopitzke, Carrie
258 Marcis, Jennifer Meece, Jennifer Moran, DeeAnn Hertel, Joshua Petrie, Miriah Rotar,
259 Carla Rottscheit, Elisha Stefanski, Sandy Strey, Melissa Strupp.
260 e. University of Arizona: Ferris Alaa Ramadan, Flavia Maria Nakayima Miro, Josue Ortiz,
261 Mokenge Ndiva Mongoh.
262 f. University of North Carolina: Ayla Bullock, Amy Yang, Quenla Haehnel, Jessica Lin,
263 Julienne Reynolds, Katherine “Katie” Murray, Miriana Moreno Zivanovich, Anna
264 McShea, Brittney Figueroa, Melody Liu.
265 g. University of Colorado: Kathleen Grice, Cameron Bendalin, Sonia Chavez, Jolie Granger.
266 • We also acknowledge the households for their participation.
267 • L. Y. H. C. thanks the CDC Steven M. Teutsch Prevention Effectiveness (PE) Fellowship.

268 Data sharing statement

269 The household data are available upon reasonable request and upon completion of required approvals.
270 The R code for estimating generation time is available at [https://github.com/CDCgov/covid-](https://github.com/CDCgov/covid-generation-time-us)
271 [generation time-us](https://github.com/CDCgov/covid-generation-time-us).

272 Disclaimer

273 The conclusions, findings, and opinions expressed by authors contributing to this article do not
274 necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public
275 Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.

276 Declaration of Generative AI and AI-assisted technologies in the 277 writing process

278 After writing the initial draft and before sending to all coauthors, ChatGPT was used to enhance the
279 clarity and coherence of the writing and to check for grammatical errors. After using this tool, the
280 authors reviewed and edited the content as needed and take full responsibility for the content of the
281 publication.

282 Declaration of interest

- 283 • M. S. S. reports a leadership role as Associate Director of the American Academy of Pediatrics'
284 Pediatric Research in Office Settings (PROS), paid to Trustees of Columbia University. All other
285 authors report no potential conflicts.
- 286 • N. M.B. reports grant/contracts from NIH to the University of North Carolina School of Medicine,
287 Doris Duke Charitable Foundation, and North Carolina Collaboratory; participation on a DSMB or
288 advisory board for the Snowball Study Technical Interchange; a leadership or fiduciary role on
289 the American Society of Tropical Medicine and Hygiene Scientific Committee; and other financial
290 or nonfinancial interests with the COVID-19 Equity Evidence Academy (RADx-UP CDCC) Steering
291 Committee and North Carolina Occupational Safety and Health Education Research Center.
- 292 • E. A. reports serving as a former consultant for Hillevax and Moderna, presenting a Merck-
293 supported lecture at the Latin American Vaccine Summit, and receipt of grant/research support
294 from Pfizer for pneumococcal pneumonia studies.
- 295 • S. R. reports grant support from BioFire.
- 296 • H. Q. N. reports grant/research support from CSL Seqirus, GSK, and ModernaTX, and honorarium
297 for participating in a consultancy group for ModernaTX outside the submitted work.
- 298 • S. H. M. reports grants/contracts from NIH, the American Academy of Pediatrics, and the Doris
299 Duke Charitable Foundation.
- 300 • E. S. reports grants or contracts to institution from Vanderbilt University Medical Center
301 (originating at CDC #75D30121C11656).
- 302 • H. K. T. has received research funding from the CDC.
- 303 • C. G. G. reports participation on an advisory board for Merck, and receipt of grant/research
304 support from AHRQ, CDC, US Food and Drug Administration, NIH, and Syneos Health.
- 305 • All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
306 Conflicts that the editors consider relevant to the content of the manuscript have been
307 disclosed.

308 Financial support

- 309 • The parent household transmission study (the Respiratory Virus Transmission Network –
310 Sentinel) was funded by the Centers for Disease Control and Prevention (Centers for Disease
311 Control and Prevention; contracts 75D30121C11656 and 75D30121C11571).
- 312 • The REDCap data tool was supported by the National Center for Advancing Translational
313 Sciences (NCATS), National Institutes of Health (grant number 5UL1TR002243-03 Clinical and
314 Translational Science Award).
- 315 • S. H. M. reports support to institution (Trustees of Columbia University) from Vanderbilt
316 University Medical Center (project 75D30121C11656).
- 317 • M. S. S. reports a subcontract from Vanderbilt University Medical Center (funding originated
318 from CDC) paid to Trustees of Columbia University.

319

320

321
322

References

- [1] Centers for Disease Control and Prevention, "Current Epidemic Growth Status (Based on Rt) for States and Territories," 22 March 2024. [Online]. Available: <https://www.cdc.gov/forecast-outbreak-analytics/about/rt-estimates.html>. [Accessed 25 March 2024].
- [2] K. M. Gostic, L. McGough, E. B. Baskerville, S. Abbott, K. Joshi, C. Tedijanto, R. Kahn, R. Niehus, J. A. Hay, P. M. De Salazar, J. Hellewell, S. Meakin, J. D. Munday, N. I. Bosse and K. Sherrat, "Practical considerations for measuring the effective reproductive number, Rt," *PLOS Computational Biology*, vol. 16, no. 12, p. e1008409, 2020.
- [3] S. W. Park, K. Sun, S. Abbott, R. Sender, Y. M. Bar-on, J. S. Weitz, S. Funk, B. T. Grenfell, J. A. Backer, J. Wallinga, C. Viboud and J. Dushoff, "Inferring the differences in incubation-period and generation-interval distributions of the Delta and Omicron variants of SARS-CoV-2," *Proceedings of the National Academy of Sciences*, vol. 120, no. 22, p. e2221887120, 2023.
- [4] Y. M. Mefsin, D. Chen, H. S. Bond, Y. Lin, J. K. Cheung, J. Y. Wong, S. T. Ali, E. H. Lau, P. Wu, G. M. Leung and others, "Epidemiology of infections with SARS-CoV-2 Omicron BA. 2 variant, Hong Kong, January–March 2022," *Emerging infectious diseases*, vol. 28, no. 9, p. 1856, 2022.
- [5] M. Manica, A. De Bellis, G. Guzzetta, P. Mancuso, M. Vicentini, F. Venturelli, R. E. C.-1. W. Group and others, "Intrinsic generation time of the SARS-CoV-2 Omicron variant: An observational study of household transmission," *The Lancet Regional Health – Europe*, vol. 19, p. 100446, 2022.
- [6] K. Wang, Z. Guo, T. Zeng, S. Sun, Y. Lu, J. Wang, S. Li, Z. Luan, H. Li, J. Zhang, Y. Wang, Y. Lu and S. Zhao, "Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China," *JAMA Network Open*, vol. 6, no. 3, p. e235755, 2023.
- [7] X. Xu, Y. Wu, A. G. Kummer, Y. Zhao, Z. Hu, Y. Wang, H. Liu, M. Ajelli and H. Yu, "Assessing changes in incubation period, serial interval, and generation time of SARS-CoV-2 variants of concern: a systematic review and meta-analysis," *BMC medicine*, vol. 21, no. 1, p. 374, 2023.
- [8] R. Pung, T. W. Russell and A. J. Kucharski, "Detecting changes in generation and serial intervals under varying pathogen biology, contact patterns and outbreak response," *PLOS Computational Biology*, vol. 20, no. 3, p. e1011967, 2024.
- [9] W. S. Hart, S. Abbott, A. Endo, J. Hellewell, E. Miller, N. rews, P. K. Maini, S. Funk and R. N. Thompson, "Inference of the SARS-CoV-2 generation time using UK household data," *eLife*, vol. 11, p. e70767, 2022.
- [10] S. E. Smith-Jeffcoat, A. M. Mellis, C. G. Grijalva, H. K. Talbot, J. Schmitz, K. Lutrick, K. D. Ellingson, M. S. Stockwell, S. H. McLaren, H. Q. Nguyen, S. Rao, E. J. Asturias and Davis-Gardner, "SARS-CoV-2 Viral Shedding and Rapid Antigen Test Performance—Respiratory Virus Transmission Network, November 2022–May 2023," *Morbidity and Mortality Weekly Report*, vol. 73, p. 365–371, 2024.

- [11] S. E. Smith-Jeffcoat, J. E. Biddle, H. K. Talbot, K. G. Morrissey, M. S. Stockwell, Y. Maldonado, H. Q. McLean, K. D. Ellingson, N. M. Bowman, E. Asturias, A. M. Mellis, S. Johnson and H. Kirking, "Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals," *Clinical Infectious Diseases*, vol. 78, no. 5, pp. 1175-1184, 2023.
- [12] M. A. Rolfes, H. K. Talbot, K. G. Morrissey, M. S. Stockwell, Y. Maldonado, H. Q. McLean, K. Lutrick, N. M. Bowman, S. Rao, H. S. Izurieta, Y. Zhu, J. Chappell, S. Battan-Wraith and Merrill, "Reduced risk of SARS-CoV-2 infection among household contacts with recent vaccination and past COVID-19 infection: results from two multi-site case-ascertained household transmission studies," *medRxiv*, pp. 2023--10, 2023.
- [13] A. M. Mellis, A. S. Luring, H. K. Talbot, H. Q. McLean, K. G. Morrissey, M. S. Stockwell, N. M. Bowman, Y. Maldonado, K. D. Ellingson, S. Rao, J. E. Biddle, S. Johnson and C. Ogokeh, "Changes in Transmission and Symptoms of SARS-CoV-2 in United States Households, April 2020–September 2022," *medRxiv*, pp. 2023--05, 2023.
- [14] S. Cauchemez, F. Carrat, C. Viboud, A. J. Valleron and P.-Y. Boëlle, "A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data," *Statistics in Medicine*, vol. 23, no. 22, pp. 3469-3487, 2004.
- [15] W. S. Hart, P. K. Maini and R. N. Thompson, "High infectiousness immediately before COVID-19 symptom onset highlights the importance of continued contact tracing," *eLife*, vol. 10, p. e65534, 2021.
- [16] W. S. Hart, E. Miller, N. J. Andrews, P. Waight, P. K. Maini, S. Funk and R. N. Thompson, "Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis," *The Lancet Infectious Diseases*, vol. 22, no. 5, pp. 603--610, 2022.
- [17] T. Ogata and H. Tanaka, "SARS-CoV-2 incubation period during the Omicron BA. 5--dominant period in Japan," *Emerging Infectious Diseases*, vol. 29, no. 3, p. 595, 2023.
- [18] M. Pastore, "Overlapping: a R package for Estimating Overlapping in Empirical Distributions," *Journal of Open Source Software*, vol. 3, no. 32, p. 1023, 2018.
- [19] M. Pastore and A. Calcagni, "Measuring Distribution Similarities Between Samples: A Distribution-Free Overlapping Index," *Frontiers in Psychology*, vol. 10, p. 1089, 2019.
- [20] A. S. Lambrou, P. Shirk, M. K. Steele, P. Paul, C. R. Paden, B. Cadwell, H. E. Reese, Y. Aoki, N. Hassell, J. Caravas, N. A. Kovacs, J. G. Gerhart, H. J. Ng and X.-y. Zheng, "Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022," *MMWR Morb Mortal Wkly Rep*, vol. 71, p. 206–211, 2022.
- [21] K. C. Ma, P. Shirk, A. S. Lambrou, N. Hassell, X.-y. Zheng, A. B. Payne, A. R. Ali, D. Batra, J. Caravas, R. Chau, P. W. Cook, D. Howard, N. A. Kovacs, K. A. Lacek and J. S. Lee, "Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron Lineages — United States, January 2022–May 2023,"

MMWR Morb Mortal Wkly Rep, vol. 72, p. 651–656, 2023.

[22] U.S. Food and Drug Administration, "SARS-CoV-2 Assay (Panther Fusion System)," 2020. [Online]. Available: <https://www.fda.gov/media/136156/download>. [Accessed 13 September 2023].

323

324

325